Professor Emeritus of Psychiatry The Ohio State University Sunbury, Ohio
Treatments with long-term benefit for attention-deficit/hyperactivity disorder (ADHD) are needed. One of the more promising is Neurofeedback (EEG Biofeedback; NF), which has several randomized controlled trials showing significant benefit, but which are inconclusive because they were not double-blinded; the benefit could have been nonspecific (placebo response). Because of Neurofeedback’s labor-intensive cost, it is important to know how much specific benefit it yields. This presentation will review and critique the evidence base for neurofeedback as treatment for ADHD and unveil preliminary results of an NIMH-funded double-blind 2-site randomized clinical trial (RCT) designed to address flaws of previous studies.
Understand the hypothesized mechanism of neurofeedback training to improve cognitive and behavioral performance by modifying abnormal EEG waves.
Discuss meta-analysis of published randomized controlled trials of neurofeedback for Attention-Deficit/Hyperactivity Disorder (ADHD).
Describe how previous studies are flawed to detect a specific effect of neurofeedback beyond the nonspecific benefit of many contacts and concerted effort.
Learn the preliminary results of an NIH-funded double-blind placebo-controlled randomized clinical trial of neurofeedback for ADHD.